Table 3 The efficacy as the percentage of patients with an ACR20 response of anti-TNF in the active drug group (Active) and daily clinical practice (DREAM)

Study	Active	Follow-up time (weeks)	Overestimation			Underestimation
Study	Active	Follow-up time (weeks)	DREAM	Δ	p Value	DREAM	Δ	p Value
Adalimumab + MTX
Weinblatt, 200316	67.2	24	54.9	−12.3	0.04411	41.8	−25.4	0.00026
Furst, 200318	52.8	24	54.9	2.1	0.66326	41.8	−11	0.01383
Keystone, 200417	63.3	24	54.9	−8.4	0.05409	41.8	−21.5	0.00003
Adalimumab mono
Van de Putte, 200319	57	12	29.0	−28.0	0.00470	22.6	−34.4	0.00069
Van de Putte, 200420	46	24	40.0	−6.0	0.29261	32.0	−14.0	0.10066
Etanercept + MTX
Weinblatt, 199910	71	24	44.5	−26.5	0.00029	31.5	−39.5	0.00000
Lan, 200411	90	12	45.7	−44.3	0.00001	34.4	−55.6	0.00000
Etanercept mono
Moreland, 19974	75	12	40.5	−34.5	0.00059	23.8	−51.2	0.00000
Moreland, 199912	59	24	31.6	−27.4	0.00280	26.3	−32.7	0.00047
Keystone, 200413	63	16	40.5	−22.5	0.00442	23.8	−39.2	0.00000
Infliximab + MTX*
ATTRACT, 99-0415	50	30	32.2	−17.8	0.01665	27.1	−22.9	0.00291

DREAM, Dutch Rheumatoid Arthritis Monitoring; MTX, methotrexate; RCT, randomised controlled trial; RF, rheumatoid factor.
Bonferroni correction resulted in a p value <0.0045 (0.05/11) being considered significant. *Maini et al14 presented only Paulus criteria in their articles.